XM does not provide services to residents of the United States of America.

French night vision firm Exosens aims to raise 180 mln euros in IPO



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-French night vision firm Exosens aims to raise $195 mln in IPO</title></head><body>

Adds background in paragraph 3; details from paragraph 8 onwards

By Mathieu Rosemain and Augustin Turpin

May 23 (Reuters) -French optical component maker Exosens is aiming to raise about 180 million euros ($195 million) through an IPO on Euronext Paris, paving the way for a partial exit for private equity firm Groupe HLD amid a return of stock listings in Europe.

The company, which provides night vision tools and photo sensor technology for defense, medical and nuclear scientific applications, is deemed strategic by the French government, which blocked its sale to a U.S. conglomerate four years ago.

It is benefiting from a boom in global military spending, with its night amplification optical tools representing two thirds of its sales. The money raised through the stock listing will be used to cut debt and make acquisitions, it said.

Exosens, formerly known as Photonis, said in a statement on Thursday that France's financial markets regulator approved its registration document, the first step for a listing process that takes weeks.

The group has still to set the price per share, which would determine the market valuation it is seeking.

HLD, owned by a group of 30 wealthy families, bought Exosens from French buyout group Ardian in 2021. It intends to sell a portion of its shares through the IPO while maintaining a controlling interest, according to the statement.

French state-owned investment bank Bpifrance intends to buy some of Exosens' new shares, Exosens said, with the aim to own 4.5% of the group after the stock listing.

Exosens employs 1,600 people and generated about 319 million euros in sales in 2023, up from 166 million in 2021, it said. It said its adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) margin was about 29% last year.

It is targeting underlying sales growth at the top of the 15%-20% range in 2024, and adjusted EBITDA of at least 115 million euros.

A string of stock listings this year has infused new life into Europe's anaemic market for IPOs.

There's been two notable company listings in Paris so far this year: the direct listing of Pluxee PLX.PA, the spun-off voucher unit of French caterer Sodexo EXHO.PA, and the IPO of French software group Planisware PLNW.PA.

($1 = 0.9238 euros)



Reporting by Mathieu Rosemain and Augustin Turpin, Editing by Dominique Vidalon, Tomasz Janowski and Muralikumar Anantharaman

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.